National Cancer Institute - U.S. National Institutes of Health - www.cancer.govSkip navigationNational Cancer Institute - U.S. National Institutes of Health - www.cancer.govClinical Trials at NIH - Be part of the cure
National Cancer Institute - U.S. National Institutes of Health - www.cancer.gov
Clinical Trials at NIH Home

Clinical Trials by Cancer Site

Melanoma

Skin cancers are formed when new cells grow when they should not and old or damaged cells do not die when they should. These extra cells can form a mass of tissue called a growth (tumor).

The most common forms of skin cancers are basal cell and squamous cell carcinomas. Both are usually found on areas of the skin that have been in the sun, although squamous cell carcinoma may begin in other parts of the body.

Melanoma is the most life-threatening type of skin cancer and grows in the skin cells called melanocytes, which are found in the lower part of the outer layer of the skin. Melanocytes make melanin, the pigment that gives skin its natural color and causes the skin to tan.

Cutaneous melanoma is the most common type of melanoma and begins in the skin where most of the melanocytes in the body are found. Both ocular (intraocular) melanoma, which is found in the eye, and mucosal melanoma, which is found in mucosal tissue linings, are very rare.

In advanced melanoma, melanoma cells can spread (metastasize) to other organs, to lymph nodes, or to skin areas far away from the original tumor.

More than 76,250* people in the United States will be newly diagnosed with melanoma in 2012.

Treatment options for melanoma vary depending on the type of melanoma, stage of the disease, previous treatment, and other medical conditions. Talk with your doctor about what treatment options may be available for you.

*American Cancer Society. Cancer Facts and Figures 2012. Atlanta: American Cancer Society; 2012

Melanoma Clinical Trials

The NCI Center for Cancer Research (CCR) conducts clinical trials at the NIH Clinical Center in Bethesda, Maryland. CCR is currently conducting the following trials for patients with melanoma. Click on the trials below for additional details, including a summary of key eligibility criteria, study outline, and information on how to contact the principal investigators and their staff directly. For information on a particular trial or to discuss a screening visit, contact a member of the research team listed on the trial’s summary.

If you need further assistance, call our toll-free number at 1-888-NCI-1937 (1-888-624-1937) to be connected to a referral coordinator appropriate for your diagnosis.


  
Trial and Protocol Number
Melanoma
Phase III
Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-dose Aldesleukin in Metastatic Melanoma
NCI-10-C-0117, NCT01118091

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase II
A Pilot Study of the Administration of Young Tumor Infiltrating Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanoma
NCI-11-C-0260, NCT01468818

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase II Study of Tumor Infiltrating Lymphocytes Generated With Engineered Cells for Costimulation Enhancement in Patients With Metastatic Melanoma Following Lymphodepletion
NCI-11-C-0163, NCT01369875

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
A Phase II Study of Lapatinib for the Treatment of Stage IV Melanoma Harboring ERBB4 Mutations
NCI-11-C-0048, NCT01264081

Principal Investigator:Referral Contact:
Udo RudloffCarole Webb
301-496-3098301-402-8475
Webbcc@mail.nih.gov
Phase II Study in Patients With Metastatic Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Tumor Reactive Peripheral Blood Lymphocytes (PBL) and High- or Low-Dose Aldesleukin
NCI-08-C-0104, NCT00665470

Principal Investigator:Referral Contact:
Udai KammulaLinda Williams
301-435-86061-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase I/II
A Phase I/II Study of IL-15 Administration Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen and Autologous Lymphocyte Transfer in Metastatic Melanoma
NCI-11-C-0170, NCT01369888

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase I/II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of CD8 Enriched Tumor Infiltrating Lymphocytes Genetically Engineered to Express IL-12
NCI-11-C-0011, NCT01236573

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase I
A Pilot Trial of the Combination of Vemurafenib With Adoptive Cell Therapy in Patients With Metastatic Melanoma
NCI-12-C-0114, NCT01585415

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
A Phase I Study of Intravenous Recombinant Human IL-15 (rhIL-15) in Adults With Metastatic Melanoma and Metastatic Renal Cell Cancer
NCI-10-C-0021, NCT01021059

Principal Investigator:Referral Contact:
Thomas WaldmannTat’Yana Worthy
301-496-6656301-496-0499
worthyt@mail.nih.gov
No Phase
Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI)
NCI-11-C-0123, NCT01319565

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov


  
Trial and Protocol Number
Lung Cancer
Phase I
Autologous Tumor Cell Vaccine and ISCOMATRIX(TM) Adjuvant With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Sarcomas, Melanomas, Germ Cell Tumors, or Epithelial Malignancies Metastatic to the Lungs, Pleura or Mediastinum
NCI-11-C-0148, NCT01341496

Principal Investigator:Referral Contact:
David S. SchrumpTricia Kunst
301-496-2128301-451-1233
tricia_kunst@nih.gov
Adjuvant Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Sarcomas, Melanomas, Germ Cell Tumors, or Epithelial Malignancies Metastatic to Lungs, Pleura, or Mediastinum
NCI-11-C-0111, NCT01313429

Principal Investigator:Referral Contact:
David S. SchrumpTricia Kunst
301-496-2128301-451-1233
tricia_kunst@nih.gov


  
Trial and Protocol Number
Solid Tumor
Phase II
Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes
NCI-08-C-0121, NCT00670748

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase I/II
Phase I/II Study of Metastatic Cancer that Expresses MAGE-A3/12 Using Lymphodepleting Conditioning Followed by Infusion of Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
NCI-11-C-0062, NCT01273181

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes
NCI-11-C-0013, NCT01218867

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase I
A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors
NCI-09-C-0019, NCT00792545

Principal Investigator:Referral Contact:
Elise C. KohnLaura D. Otten
301-402-2726301-451-1228
1-866-611-6310 (Toll Free)
ottenl@mail.nih.gov


Back to Top
Health and Human Services National Institutes of Health National Cancer Institute USA.gov